Sugi Predict

Sugi Predict / Compounds / SCHEMBL29732500

SCHEMBL29732500

SCHEMBL29732500

CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 12/20 0.56
▸ NPY1R P25929 7/20 0.56
▸ NPY2R P49146 5/20 0.56
▸ NPY5R Q15761 5/20 0.56
▸ GNPAT O15228 1/20 0.52
▸ KISS1R Q969F8 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ BACE1 P56817 1/20 0.48
▸ CTSK P43235 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798743 0.96 NPY4R (0.60) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL11302814 0.96 NPY4R (0.50) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL11302796 0.96 NPY4R (0.50) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL30302999 0.93 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL23142771 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29652148 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL30051461 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL30051400 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29652154 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT
SCHEMBL29652137 0.92 NPY4R (0.58) NPY4RNPY1RNPY2RNPY5RGNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250277002-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE PEPTILOGICS, INC. 2025-09-04 — — US disclosed
US-20240115654-A1 INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES PEPTILOGICS, INC. 2024-04-11 — — US disclosed
US-20230107222-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE PEPTILOGICS, INC. 2023-04-06 — — US disclosed
US-20220249599-A1 TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES PEPTILOGICS, INC. 2022-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249599-A1 TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES NGLY1, ANPEP, VIP NPY4R 3342/4885NPY1R 2801/4885NPY2R 3431/4885
US-20240115654-A1 INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES IAPP, VIP, NGLY1 NPY4R 3117/4885NPY1R 2841/4885NPY2R 3413/4885
US-20250277002-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE NGLY1, PRF1, LNPEP NPY4R 3510/4885NPY1R 3504/4885NPY2R 3813/4885
US-20230107222-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE NGLY1, PRF1, LNPEP NPY4R 3510/4885NPY1R 3504/4885NPY2R 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.